Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19304098 | 0.90 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1HTTHPGDL3MBTL1 | |
| SCHEMBL1902358 | 0.84 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1HTTHPGDL3MBTL1 | |
| SCHEMBL7456756 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1HTTHPGDL3MBTL1 | |
| SCHEMBL8293397 | 0.84 | HTT (0.71) | SMN1; SMN2ALDH1A1HTTHPGDL3MBTL1 | |
| SCHEMBL7459479 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HTTHPGDL3MBTL1 | |
| SCHEMBL20676018 | 0.81 | SMN1; SMN2 (0.85) | SMN1; SMN2ALDH1A1HTTHPGDTDP1 | |
| SCHEMBL19850342 | 0.80 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1HTTHPGDL3MBTL1 | |
| SCHEMBL28007888 | 0.80 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1HTTL3MBTL1KMT2A | |
| SCHEMBL15800410 | 0.79 | S1PR1 (0.62) | ALDH1A1HTTKDM4EKMT2AMEN1 | |
| SCHEMBL14145859 | 0.77 | POLB (0.51) | SMN1; SMN2ALDH1A1HPGDKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| EP-4304630-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | Research Triangle Institute (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-116963761-A | Small molecule antagonists against relaxin-3/RXFP 3 system | 研究三角协会 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022192126-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE (US) | 2022-09-15 | — | — | WO | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RXFP3, RXFP1, RXFP4 | SMN1; SMN2 3711/4885ALDH1A1 3341/4885HTT 1614/4885 |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | SMN1; SMN2 199/4885ALDH1A1 2023/4885HTT 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.